Seeking Alpha

Medivation (MDVN +0.75%) and not Dendreon (DNDN -3.5%) is the more attractive acquisition...

Medivation (MDVN +0.75%) and not Dendreon (DNDN -3.5%) is the more attractive acquisition target, says Jefferies analyst Biren Amin. This is because of the bright prospects for MDV3100, the prostate-cancer drug that Medivation half owns and the poor outlook for provenge, Dendreon's rival treatment.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs